Depriving Tumor Cells of Ways to Metastasize: Ferroptosis Nanotherapy Blocks Both Hematogenous Metastasis and Lymphatic Metastasis
Source abstract
Abstract
Blood and lymph are two main pathways of tumor metastasis; however, hematogenous metastasis and lymphatic metastasis are difficult to inhibit simultaneously. Ferroptosis provides a new breakthrough for metastasis inhibition, but how to effectively trigger ferroptosis in tumor cells remains a major challenge. Metastatic tumor cells are prone to ferroptosis in blood, while they may be protected from ferroptosis in lymph. In this study, a nanoplatform DA/RSL3 was constructed for the intracellular codelivery of the polyunsaturated arachidonic acid (AA) and the GPX4 inhibitor RSL3, which could not only induce ferroptosis but also alleviate ferroptosis resistance. As a result, DA/RSL3 effectively triggered ferroptosis in tumor cells, thereby impairing the ability of tumor cells to metastasize in both blood and lymph. Furthermore, a fucoidan blocking strategy was proposed to maximize the efficacy of DA/RSL3. Fu+DA/RSL3 showed excellent efficacy in 4T1 tumor-bearing mice. This ferroptosis nanotherapy is promising for metastatic cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · Epigenetics and DNA Methylation · Cancer, Lipids, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Med-X Center for Materials, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
Funding
Sichuan University · Department of Science and Technology of Sichuan Province · National Natural Science Foundation of China
References (28)
Show source-provided references
1. 10.1038/ncponc106610.1038/ncponc1066 ↗
2. 10.1038/nrc262210.1038/nrc2622 ↗
3. 10.1016/j.cell.2011.09.02410.1016/j.cell.2011.09.024 ↗
4. 10.1126/science.aai851510.1126/science.aai8515 ↗
5. 10.1126/science.aal366210.1126/science.aal3662 ↗
6. 10.1038/nm.339110.1038/nm.3391 ↗
7. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
8. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
9. 10.1038/s41422-020-00441-110.1038/s41422-020-00441-1 ↗
10. 10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
11. 10.1038/nature1572610.1038/nature15726 ↗
12. 10.1038/s41467-022-29018-910.1038/s41467-022-29018-9 ↗
13. 10.1038/s41586-020-2623-z10.1038/s41586-020-2623-z ↗
14. 10.1038/s41467-021-25354-410.1038/s41467-021-25354-4 ↗
15. 10.1038/nature0638510.1038/nature06385 ↗
16. 10.1126/science.aal362210.1126/science.aal3622 ↗
17. 10.1186/s12935-021-02057-w10.1186/s12935-021-02057-w ↗
18. 10.1016/j.apsb.2021.05.01210.1016/j.apsb.2021.05.012 ↗
19. 10.1021/acsnano.7b0673410.1021/acsnano.7b06734 ↗
20. 10.4049/jimmunol.100098910.4049/jimmunol.1000989 ↗
21. 10.1016/j.intimp.2019.10582310.1016/j.intimp.2019.105823 ↗
22. 10.1016/j.biomaterials.2017.11.04710.1016/j.biomaterials.2017.11.047 ↗
23. 10.1016/j.biomaterials.2018.12.02310.1016/j.biomaterials.2018.12.023 ↗
24. 10.1038/nrc300410.1038/nrc3004 ↗
25. 10.1182/blood-2014-08-53158210.1182/blood-2014-08-531582 ↗
26. 10.1126/scitranslmed.aaf737410.1126/scitranslmed.aaf7374 ↗
27. 10.1021/acs.nanolett.9b0388310.1021/acs.nanolett.9b03883 ↗
28. 10.1186/s13058-015-0558-310.1186/s13058-015-0558-3 ↗